Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) EBITDA (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed EBITDA for 6 consecutive years, with -$61.2 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 19.66% to -$61.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$230.4 million, a 36.82% decrease, with the full-year FY2024 number at -$187.8 million, down 66.43% from a year prior.
  • EBITDA was -$61.2 million for Q3 2025 at 4D Molecular Therapeutics, down from -$59.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$7.6 million in Q2 2021 to a low of -$61.2 million in Q3 2025.
  • A 5-year average of -$34.5 million and a median of -$30.1 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: skyrocketed 49.86% in 2021, then plummeted 274.22% in 2022.
  • 4D Molecular Therapeutics' EBITDA stood at -$24.8 million in 2021, then decreased by 15.97% to -$28.7 million in 2022, then fell by 27.61% to -$36.7 million in 2023, then plummeted by 53.11% to -$56.1 million in 2024, then fell by 9.03% to -$61.2 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's EBITDA are -$61.2 million (Q3 2025), -$59.5 million (Q2 2025), and -$53.6 million (Q1 2025).